Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver

One of the biggest challenges facing genetic medicines is getting them to the right part of the body. Little balls of fat called lipid nanoparticles used to carry mRNA can be injected into the arm for vaccines or infused into the blood to shuttle genetic medicines to the liver. But delivering the molecules to other cells or organs remains a challenge.

A new startup called Mana.bio hopes to change that, Endpoints News has learned. Based in Tel Aviv, Israel, Mana.bio has raised $19.5 million in seed financing from Andreessen Horowitz Bio + Health (a16z), Base4 Capital, NFX, LionBird and Technion — Israel Institute of Technology.

Read the full article here